we should have biopsy to check cccdna so that we know if we can stop safely but biopsy is so bad....they wanted to make it to me to see all virus parameters correctly but i really dont like it, i felt so bad after biopsies in the past, the first time almost lost all my hair and i was only 19yo....
Interesting theory, hope that will be follow up.
Indeed, monitoring after stopping antivirals is essential and have to be put it like mandatory in all guidelines.
Yes, it was a 2002 paper, hopefully treatments have advanced since. Just read this in the HBV Journal Review, Oct 1, 2011:
The antiviral lamivudine (Epivir-HBV) has fallen out of favor as an antiviral treatment for hepatitis B because it causes drug resistance.
However, a study reported in the Digestive Diseases and Sciences found the antiviral was effective when administered in high doses in patients with cirrhosis.
Researchers treated six people with HBV-related cirrhosis with lamivudine doses raised from the normal dose of 100 mg daily to 200 or 300 mg daily, based on their viral load. Previously, nearly all of these patients had developed lamivudine resistance at the lower, 100 mg-dose, and had failed to improve even after the antiviral adefovir (Hepsera) (10 mg daily) was added to their ongoing lamivudine treatment.
The HBeAg-negative patients continued to receive adefovir, but the lamivudine dose was hiked for 12 months. All achieved a “significant” decrease in HBV DNA, three of the patients achieved undetectable viral load within six months. All achieved normal ALT levels, indicating no liver damage. The higher dose did not adversely impact their kidney function, nor were any other side effects noted.
The researchers suggested that increased doses of any antiviral—not just lamivudine—may be effective in hard-to-treat patients with life-threatening cirrhosis or liver damage.
So increased doses of antiviral may help. Frequent monitoring after stopping antivirals is essential, I think.
i think studies like that in rome could be very useful.......
i actually called for an hbvdna with imprved sensibility at 6 iu/ml but the biologist said it is no use to go lower than that because we have full genome check so we can say how the drug is doing despite the hbvdna levels and predict resistance or how the drug performs
if the quasispieces changes stop etv showed hbsag clearance and this is a very interesting finding
that's why i am adding ntz and sim to etv and checking full genome, in my case death is extremely easy if the rise in hbvdna goes unchecked for long
once these nucs are started we must watch very carefully for resistance, they are not sweeties even today with tnf
4est:
that's about the same if resistance develops even on etv while we are lucky tnf has no resistnce so that is the only very safe choice on nucs today
I thinck that this was a 2002 article and no other option then lamivudine exist at that time.
it will be interesting to see if in case of other nucs something similar was observed.
Thanks, I did not see the word "fatal". It is scary, especially in the case of the patient without cirrhosis. I noticed the ALTs were normal when therapy was stopped, then rose after stopping. Even when lamivudine was resumed, it did not stop the rise in ALT, which then down eventually, but the bilirubins did not. May be compensated cirrhosis patients should never stop therapy, and those on lamivudine should switch to a drug with a higher barrier to mutation?
it says fatal, they re all dead.in liver failure you have normal alt etc but bilirubin, PT and platlets which reflect liver function all go bad
once the liver reaches decompensation you dnt receover damage even if you survive, it is like fulminant hepatitis you reaches cirrhosis, liver decompensation, liver failure and death in days
I wonder whether these three patients survived? Their ALTs all returned to normal after re-introduction of lamivudine therapy, but not their Bilirubin levels.